Download PDF
Semin Thromb Hemost 2009; 35(7): 621-629
DOI: 10.1055/s-0029-1242716
© Thieme Medical Publishers

Thrombosis in Systemic Lupus Erythematosus

Anita Palatinus1 , Murray Adams1
  • 1School of Human Life Sciences, University of Tasmania, Tasmania, Australia
Further Information

Publication History

Publication Date:
09 December 2009 (online)

    Permissions and Reprints

ABSTRACT

Systemic lupus erythematosus (SLE) is a potentially fatal multiorgan inflammatory disease that primarily affects females. Due to the heterogeneity of clinical manifestations and lack of laboratory tests that are both specific and sensitive for the disease, diagnosis of SLE can often be difficult. Although the precise etiology remains to be fully elucidated, it is probable that various environmental, genetic, and hormonal factors contribute to the development of the disease. Patients with SLE have an increased risk for premature thrombosis and/or atherosclerosis, with up to half experiencing a thrombotic event. Furthermore, antiphospholipid antibodies probably play a key role in the development of thrombosis by affecting various hemostatic protein interactions with phospholipids and cell surfaces as well as platelet function. Despite recent advances in knowledge related to the factors that contribute to the pathophysiology of SLE, numerous challenges related to earlier diagnosis as well as the prediction and prevention of thrombotic events remain to be fully addressed.

KEYWORDS

Systemic lupus erythematosus - lupus - thrombosis - antiphospholipid antibody

REFERENCES

  • 1 Swigris J J, Fischer A, Gillis J, Meehan R T, Brown K K. Pulmonary and thrombotic manifestations of systemic lupus erythematosus.  Chest. 2008;  133(1) 271-280
    CrossrefPubMedGoogle Scholar
  • 2 Cervera R, Khamashta M A, Font J European Working Party on Systemic Lupus Erythematosus et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients.  Medicine (Baltimore). 2003;  82(5) 299-308
    CrossrefPubMedGoogle Scholar
  • 3 Cervera R, Khamashta M A, Font J European Working Party on Systemic Lupus Erythematosus et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients.  Medicine (Baltimore). 1999;  78(3) 167-175
    CrossrefPubMedGoogle Scholar
  • 4 McClain M T, Arbuckle M R, Heinlen L D et al.. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus.  Arthritis Rheum. 2004;  50(4) 1226-1232
    CrossrefPubMedGoogle Scholar
  • 5 Asherson R A. The primary, secondary, catastrophic, and seronegative variants of the antiphospholipid syndrome: a personal history long in the making.  Semin Thromb Hemost. 2008;  34(3) 227-235
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Danchenko N, Satia J A, Anthony M S. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden.  Lupus. 2006;  15(5) 308-318
    CrossrefPubMedGoogle Scholar
  • 7 D'Cruz D P. Systemic lupus erythematosus.  BMJ. 2006;  332(7546) 890-894
    CrossrefPubMedGoogle Scholar
  • 8 Petri M. Sex hormones and systemic lupus erythematosus.  Lupus. 2008;  17(5) 412-415
    CrossrefPubMedGoogle Scholar
  • 9 Rahman A, Isenberg D. Systemic lupus erythematosus.  N Engl J Med. 2008;  358 929-939
    CrossrefPubMedGoogle Scholar
  • 10 Mills J A. Systemic lupus erythematosus.  N Engl J Med. 1994;  330(26) 1871-1879
    CrossrefPubMedGoogle Scholar
  • 11 Panjwani S. Early diagnosis and treatment of discoid lupus erythematosus.  J Am Board Fam Med. 2009;  22(2) 206-213
    CrossrefPubMedGoogle Scholar
  • 12 van Vugt R M, Derksen R H, Kater L, Bijlsma J W. Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus.  Ann Rheum Dis. 1998;  57(9) 540-544
    CrossrefPubMedGoogle Scholar
  • 13 Wang Z, Tang Z, Zhang H T, Hu W X, Liu Z H, Li L S. Clinicopathological characteristics of familial SLE patients with lupus nephritis.  Lupus. 2009;  18(3) 243-248
    CrossrefPubMedGoogle Scholar
  • 14 Mosley K, Tam F W, Edwards R J, Crozier J, Pusey C D, Lightstone L. Urinary proteomic profiles distinguish between active and inactive lupus nephritis.  Rheumatology (Oxford). 2006;  45(12) 1497-1504
    CrossrefPubMedGoogle Scholar
  • 15 Cervera R, Font J, Paré C et al.. Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients.  Ann Rheum Dis. 1992;  51(2) 156-159
    CrossrefPubMedGoogle Scholar
  • 16 Frostegård J. Systemic lupus erythematosus and cardiovascular disease.  Lupus. 2008;  17(5) 364-367
    CrossrefPubMedGoogle Scholar
  • 17 Hahn B H. Systemic lupus erythematosus and accelerated atherosclerosis.  N Engl J Med. 2003;  349(25) 2379-2380
    CrossrefPubMedGoogle Scholar
  • 18 Salmon J E, de Groot P G. Pathogenic role of antiphospholipid antibodies.  Lupus. 2008;  17(5) 405-411
    CrossrefPubMedGoogle Scholar
  • 19 Kim S Y, Lee J H. Prognosis of neonates in pregnant women with systemic lupus erythematosus.  Yonsei Med J. 2008;  49(4) 515-520
    CrossrefPubMedGoogle Scholar
  • 20 Yan Yuen S, Krizova A, Ouimet J M, Pope J E. Pregnancy outcome in systemic lupus erythematosus (SLE) is improving: results from a case control study and literature review.  Open Rheumatol J. 2008;  2 89-98
    PubMedGoogle Scholar
  • 21 Doria A, Tincani A, Lockshin M. Challenges of lupus pregnancies.  Rheumatology (Oxford). 2008;  47(Suppl 3) iii9-iii12
    CrossrefPubMedGoogle Scholar
  • 22 Ginsberg J S, Brill-Edwards P, Johnston M et al.. Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: a cross-sectional study.  Blood. 1992;  80(4) 975-980
    PubMedGoogle Scholar
  • 23 Giannouli S, Voulgarelis M, Ziakas P D, Tzioufas A G. Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment.  Ann Rheum Dis. 2006;  65(2) 144-148
    CrossrefPubMedGoogle Scholar
  • 24 Voulgarelis M, Kokori S I, Ioannidis J P, Tzioufas A G, Kyriaki D, Moutsopoulos H M. Anaemia in systemic lupus erythematosus: aetiological profile and the role of erythropoietin.  Ann Rheum Dis. 2000;  59(3) 217-222
    CrossrefPubMedGoogle Scholar
  • 25 Kuwana M, Kaburaki J, Okazaki Y, Miyazaki H, Ikeda Y. Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus.  Rheumatology (Oxford). 2006;  45(7) 851-854
    CrossrefPubMedGoogle Scholar
  • 26 Criswell L A. The genetic contribution to systemic lupus erythematosus.  Bull NYU Hosp Jt Dis. 2008;  66(3) 176-183
    PubMedGoogle Scholar
  • 27 Cooper G S, Gilbert K M, Greidinger E L et al.. Recent advances and opportunities in research on lupus: environmental influences and mechanisms of disease.  Environ Health Perspect. 2008;  116(6) 695-702
    CrossrefPubMedGoogle Scholar
  • 28 Cross L S, Aslam A, Misbah S A. Antinuclear antibody-negative lupus as a distinct diagnostic entity—does it no longer exist?.  QJM. 2004;  97(5) 303-308
    CrossrefPubMedGoogle Scholar
  • 29 Reichlin M. ANA negative systemic lupus erythematosus sera revisited serologically.  Lupus. 2000;  9(2) 116-119
    CrossrefPubMedGoogle Scholar
  • 30 Witte T, Hartung K, Sachse C SLE Study Group et al. IgM anti-dsDNA antibodies in systemic lupus erythematosus: negative association with nephritis.  Rheumatol Int. 1998;  18(3) 85-91
    CrossrefPubMedGoogle Scholar
  • 31 Koffler D, Agnello V, Kimkel H G. Polynucleotide immune complexes in serum and glomeruli of patients with systemic lupus erythematosus.  Am J Pathol. 1974;  74(1) 109-124
    PubMedGoogle Scholar
  • 32 Tsao B P, Ebling F M, Roman C, Panosian-Sahakian N, Calame K, Hahn B H. Structural characteristics of the variable regions of immunoglobulin genes encoding a pathogenic autoantibody in murine lupus.  J Clin Invest. 1990;  85(2) 530-540
    CrossrefPubMedGoogle Scholar
  • 33 Satoh M, Kumar A, Kanwar Y S, Reeves W H. Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane.  Proc Natl Acad Sci U S A. 1995;  92(24) 10934-10938
    CrossrefPubMedGoogle Scholar
  • 34 Ruiz-Irastorza G, Egurbide M V, Martinez-Berriotxoa A, Ugalde J, Aguirre C. Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus.  Lupus. 2004;  13(12) 900-905
    CrossrefPubMedGoogle Scholar
  • 35 Miyakis S, Lockshin M D, Atsumi T et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).  J Thromb Haemost. 2006;  4(2) 295-306
    CrossrefPubMedGoogle Scholar
  • 36 Swadzba J, De Clerck L S, Stevens W J et al.. Anticardiolipin, anti-beta(2)-glycoprotein I, antiprothrombin antibodies, and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis.  J Rheumatol. 1997;  24(9) 1710-1715
    PubMedGoogle Scholar
  • 37 Oosting J D, Derksen R H, Bobbink I W, Hackeng T M, Bouma B N, de Groot P G. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?.  Blood. 1993;  81(10) 2618-2625
    CrossrefPubMedGoogle Scholar
  • 38 Favaloro E J, Wong R C. Laboratory testing and identification of antiphospholipid antibodies and the antiphospholipid syndrome: a potpourri of problems, a compilation of possible solutions.  Semin Thromb Hemost. 2008;  34(4) 389-410
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Feinbloom D, Bauer K A. Assessment of hemostatic risk factors in predicting arterial thrombotic events.  Arterioscler Thromb Vasc Biol. 2005;  25(10) 2043-2053
    CrossrefPubMedGoogle Scholar
  • 40 Toloza S M, Uribe A G, McGwin Jr G LUMINA Study Group et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events.  Arthritis Rheum. 2004;  50(12) 3947-3957
    CrossrefPubMedGoogle Scholar
  • 41 Manzi S, Meilahn E N, Rairie J E et al.. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study.  Am J Epidemiol. 1997;  145(5) 408-415
    CrossrefPubMedGoogle Scholar
  • 42 Ho K T, Ahn C W, Alarcón G S et al.. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events.  Rheumatology (Oxford). 2005;  44(10) 1303-1307
    CrossrefPubMedGoogle Scholar
  • 43 Love P E, Santoro S A. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance.  Ann Intern Med. 1990;  112(9) 682-698
    CrossrefPubMedGoogle Scholar
  • 44 Kaiser R, Cleveland C M, Criswell L A. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort.  Ann Rheum Dis. 2009;  68(2) 238-241
    CrossrefPubMedGoogle Scholar
  • 45 Arnout J, Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease.  J Thromb Haemost. 2003;  1(5) 931-942
    CrossrefPubMedGoogle Scholar
  • 46 Sallai K K, Nagy E, Bodó I, Mohl A, Gergely P. Thrombosis risk in systemic lupus erythematosus: the role of thrombophilic risk factors.  Scand J Rheumatol. 2007;  36(3) 198-205
    CrossrefPubMedGoogle Scholar
  • 47 Kinev A V, Roubey R A. Tissue factor in the antiphospholipid syndrome.  Lupus. 2008;  17(10) 952-958
    PubMedGoogle Scholar
  • 48 Tektonidou M G, Laskari K, Panagiotakos D B, Moutsopoulos H M. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.  Arthritis Rheum. 2009;  61(1) 29-36
    CrossrefPubMedGoogle Scholar
  • 49 Khamashta M A, Cuadrado M J, Mujic F, Taub N A, Hunt B J, Hughes G R. The management of thrombosis in the antiphospholipid-antibody syndrome.  N Engl J Med. 1995;  332(15) 993-997
    CrossrefPubMedGoogle Scholar
  • 50 Rosove M H, Brewer P M. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.  Ann Intern Med. 1992;  117(4) 303-308
    CrossrefPubMedGoogle Scholar
  • 51 Anders H J. Predicting thrombosis in systemic lupus erythematosus.  Nat Clin Pract Nephrol. 2009;  5(2) 68-69
    CrossrefPubMedGoogle Scholar
  • 52 Wu H, Birmingham D J, Rovin B et al.. D-dimer level and the risk for thrombosis in systemic lupus erythematosus.  Clin J Am Soc Nephrol. 2008;  3(6) 1628-1636
    CrossrefPubMedGoogle Scholar
  • 53 Forastiero R R, Martinuzzo M E, de Larrañaga G F. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies.  Lupus. 2005;  14(2) 129-136
    CrossrefPubMedGoogle Scholar
  • 54 Nemerson Y. Tissue factor and hemostasis.  Blood. 1988;  71(1) 1-8
    PubMedGoogle Scholar
  • 55 de Prost D, Ollivier V, Ternisien C, Chollet-Martin S. Increased monocyte procoagulant activity independent of the lupus anticoagulant in patients with systemic lupus erythematosus.  Thromb Haemost. 1990;  64(2) 216-221
    PubMedGoogle Scholar
  • 56 Zhou H, Wolberg A S, Roubey R A. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep.  Blood. 2004;  104(8) 2353-2358
    CrossrefPubMedGoogle Scholar
  • 57 Martini F, Farsi A, Gori A M et al.. Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus.  Lupus. 1996;  5(3) 206-211
    CrossrefPubMedGoogle Scholar
  • 58 Forastiero R R, Martinuzzo M E, Broze G J. High titers of autoantibodies to tissue factor pathway inhibitor are associated with the antiphospholipid syndrome.  J Thromb Haemost. 2003;  1(4) 718-724
    CrossrefPubMedGoogle Scholar
  • 59 Adams M, Breckler L, Stevens P, Thom J, Baker R, Oostryck R. Anti-tissue factor pathway inhibitor activity in subjects with antiphospholipid syndrome is associated with increased thrombin generation.  Haematologica. 2004;  89(8) 985-990
    PubMedGoogle Scholar
  • 60 Lean S Y, Ellery P, Ivey L et al.. The effects of tissue factor pathway inhibitor and anti-beta-2-glycoprotein-I IgG on thrombin generation.  Haematologica. 2006;  91(10) 1360-1366
    PubMedGoogle Scholar
  • 61 Roubey R A. Mechanisms of autoantibody-mediated thrombosis.  Lupus. 1998;  7(Suppl 2) S114-S119
    CrossrefPubMedGoogle Scholar
  • 62 Galli M, Ruggeri L, Barbui T. Differential effects of anti-beta2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C.  Blood. 1998;  91(6) 1999-2004
    PubMedGoogle Scholar
  • 63 Pierangeli S, Mariano E, Vega-Ostertag M et al.. New targeted therapies for treatment of thrombosis in antiphospholipid syndrome.  Expert Rev Mol Med. 2007;  9 1-15
    PubMedGoogle Scholar
  • 64 Roubey R A. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other “antiphospholipid” autoantibodies.  Blood. 1994;  84(9) 2854-2867
    PubMedGoogle Scholar
  • 65 Nojima J, Kuratsune H, Suehisa E, Iwatani Y, Kanakura Y. Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism.  Clin Chem. 2005;  51(3) 545-552
    CrossrefPubMedGoogle Scholar
  • 66 Ekdahl K N, Bengtsson A A, Andersson J et al.. Thrombotic disease in systemic lupus erythematosus is associated with a maintained systemic platelet activation.  Br J Haematol. 2004;  125(1) 74-78
    CrossrefPubMedGoogle Scholar
  • 67 Lutters B C, Derksen R H, Tekelenburg W L, Lenting P J, Arnout J, de Groot P G. Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2′.  J Biol Chem. 2003;  278(36) 33831-33838
    CrossrefPubMedGoogle Scholar
  • 68 Urbanus R T, Derksen R H, de Groot P G. Platelets and the antiphospholipid syndrome.  Lupus. 2008;  17(10) 888-894
    CrossrefPubMedGoogle Scholar
  • 69 Dhar J P, Andersen J, Essenmacher L, Ager J, Bentley G, Sokol R J. Thrombophilic patterns of coagulation factors in lupus.  Lupus. 2009;  18(5) 400-406
    CrossrefPubMedGoogle Scholar
  • 70 Pereira J, Alfaro G, Goycoolea M et al.. Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state.  Thromb Haemost. 2006;  95(1) 94-99
    PubMedGoogle Scholar
  • 71 Danese S, de la Motte C, Reyes B M, Sans M, Levine A D, Fiocchi C. Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification.  J Immunol. 2004;  172(4) 2011-2015
    PubMedGoogle Scholar
  • 72 Joseph J E, Harrison P, Mackie I J, Isenberg D A, Machin S J. Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis.  Br J Haematol. 2001;  115(2) 451-459
    CrossrefPubMedGoogle Scholar
  • 73 Nojima J, Kuratsune H, Suehisa E, Kitani T, Iwatani Y, Kanakura Y. Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies—co-existence of these antibodies enhances ADP-induced platelet activation in vitro.  Thromb Haemost. 2004;  91(5) 967-976
    PubMedGoogle Scholar
  • 74 Jankowski M, Vreys I, Wittevrongel C et al.. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster.  Blood. 2003;  101(1) 157-162
    CrossrefPubMedGoogle Scholar
  • 75 Dorsch C, Meyerhoff J. Elevated plasma beta-thromboglobulin levels in systemic lupus erythematosus.  Thromb Res. 1980;  20(5-6) 617-622
    CrossrefPubMedGoogle Scholar
  • 76 Ekdahl K N, Rönnblom L, Sturfelt G, Nilsson B. Increased phosphate content in complement component C3, fibrinogen, vitronectin, and other plasma proteins in systemic lupus erythematosus: covariation with platelet activation and possible association with thrombosis.  Arthritis Rheum. 1997;  40(12) 2178-2186
    CrossrefPubMedGoogle Scholar
  • 77 Lockshin M D. Update on antiphospholipid syndrome.  Bull NYU Hosp Jt Dis. 2008;  66(3) 195-197
    PubMedGoogle Scholar
  • 78 Afeltra A, Vadacca M, Conti L et al.. Thrombosis in systemic lupus erythematosus: congenital and acquired risk factors.  Arthritis Rheum. 2005;  53(3) 452-459
    CrossrefPubMedGoogle Scholar
  • 79 Lincz L F, Adams M J, Scorgie F E, Thom J, Baker R I, Seldon M. Polymorphisms of the tissue factor pathway inhibitor gene are associated with venous thromboembolism in the antiphospholipid syndrome and carriers of factor V Leiden.  Blood Coagul Fibrinolysis. 2007;  18(6) 559-564
    CrossrefPubMedGoogle Scholar
  • 80 Tan E M, Cohen A S, Fries J F et al.. The 1982 revised criteria for the classification of systemic lupus erythematosus.  Arthritis Rheum. 1982;  25(11) 1271-1277
    CrossrefPubMedGoogle Scholar
  • 81 Gill J M, Quisel A M, Rocca P V, Walters D T. Diagnosis of systemic lupus erythematosus.  Am Fam Physician. 2003;  68(11) 2179-2186
    PubMedGoogle Scholar
  • 82 Hochberg M C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.  Arthritis Rheum. 1997;  40(9) 1725
    PubMedGoogle Scholar
  • 83 Fernando M M, Stevens C R, Sabeti P C et al.. Identification of two independent risk factors for lupus within the MHC in United Kingdom families.  PLoS Genet. 2007;  3(11) e192
    CrossrefPubMedGoogle Scholar
  • 84 Graham R R, Ortmann W, Rodine P et al.. Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE.  Eur J Hum Genet. 2007;  15(8) 823-830
    CrossrefPubMedGoogle Scholar
  • 85 Graham R R, Ortmann W A, Langefeld C D et al.. Visualizing human leukocyte antigen class II risk haplotypes in human systemic lupus erythematosus.  Am J Hum Genet. 2002;  71(3) 543-553
    CrossrefPubMedGoogle Scholar
  • 86 Walport M J. Complement and systemic lupus erythematosus.  Arthritis Res. 2002;  4(Suppl 3) S279-S293
    CrossrefPubMedGoogle Scholar
  • 87 Prokunina L, Castillejo-López C, Oberg F et al.. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans.  Nat Genet. 2002;  32(4) 666-669
    CrossrefPubMedGoogle Scholar
  • 88 Chung S A, Criswell L A. PTPN22: its role in SLE and autoimmunity.  Autoimmunity. 2007;  40(8) 582-590
    CrossrefPubMedGoogle Scholar
  • 89 Kyogoku C, Langefeld C D, Ortmann W A et al.. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE.  Am J Hum Genet. 2004;  75(3) 504-507
    CrossrefPubMedGoogle Scholar
  • 90 Graham R R, Kozyrev S V, Baechler E C Argentine and Spanish Collaborative Groups et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus.  Nat Genet. 2006;  38(5) 550-555
    CrossrefPubMedGoogle Scholar
  • 91 Graham R R, Kyogoku C, Sigurdsson S et al.. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus.  Proc Natl Acad Sci U S A. 2007;  104(16) 6758-6763
    CrossrefPubMedGoogle Scholar
  • 92 Sigurdsson S, Nordmark G, Göring H H et al.. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus.  Am J Hum Genet. 2005;  76(3) 528-537
    CrossrefPubMedGoogle Scholar
  • 93 Karassa F B, Trikalinos T A, Ioannidis J P. FcgammaRIIa-SLE Meta-Analysis Investigators . Role of the Fcgamma receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis.  Arthritis Rheum. 2002;  46(6) 1563-1571
    CrossrefPubMedGoogle Scholar
  • 94 Karassa F B, Trikalinos T A, Ioannidis J P. Fc gamma RIIIA-SLE meta-analysis investigators . The Fc gamma RIIIA-F158 allele is a risk factor for the development of lupus nephritis: a meta-analysis.  Kidney Int. 2003;  63(4) 1475-1482
    CrossrefPubMedGoogle Scholar
  • 95 Russell A I, Cunninghame Graham D S, Shepherd C et al.. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus.  Hum Mol Genet. 2004;  13(1) 137-147
    CrossrefPubMedGoogle Scholar
  • 96 Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz H G, Möröy T. Features of systemic lupus erythematosus in Dnase1-deficient mice.  Nat Genet. 2000;  25(2) 177-181
    CrossrefPubMedGoogle Scholar
  • 97 Yasutomo K, Horiuchi T, Kagami S et al.. Mutation of DNASE1 in people with systemic lupus erythematosus.  Nat Genet. 2001;  28(4) 313-314
    CrossrefPubMedGoogle Scholar
  • 98 Remmers E F, Plenge R M, Lee A T et al.. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus.  N Engl J Med. 2007;  357(10) 977-986
    CrossrefPubMedGoogle Scholar

Murray AdamsPh.D. M.A.I.M.S. 

Senior Lecturer, School of Human Life Sciences

University of Tasmania, Tasmania, Australia

Email: Murray.Adams@utas.edu.au